Biogen 2029 increased by 9.5% to $575.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.7%, from $630.00M to $575.00M. Over 3 years (FY 2020 to FY 2023), 2029 shows an upward trend with a 31.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Consistent projections allow for better predictability of future earnings and non-cash charges.
This represents the projected amortization expense for finite-lived intangible assets for the year 2029. It is a forward...
Standard disclosure for banks with significant historical acquisition activity.
other_finite_lived_intangible_assets_amortization_expens_a9462e| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $225.00M | $195.00M | $195.00M | $195.00M | $195.00M | $190.00M | $190.00M | $175.00M | $175.00M | $440.00M | $485.00M | $685.00M | $680.00M | $585.00M | $630.00M | $630.00M | $525.00M | $575.00M |
| QoQ Change | — | -13.3% | +0.0% | +0.0% | +0.0% | -2.6% | +0.0% | -7.9% | +0.0% | +151.4% | +10.2% | +41.2% | -0.7% | -14.0% | +7.7% | +0.0% | -16.7% | +9.5% |
| YoY Change | — | — | — | — | -13.3% | -2.6% | -2.6% | -10.3% | -10.3% | +131.6% | +155.3% | +291.4% | +288.6% | +33.0% | -8.0% | -7.4% | -10.3% | -8.7% |